A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee

PHASE2CompletedINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

March 29, 2012

Primary Completion Date

November 11, 2013

Study Completion Date

November 21, 2013

Conditions
Osteoarthritis of the Knee
Interventions
DRUG

Gefapixant

BID

DRUG

Sugar Pill

Placebo

Trial Locations (34)

16635

Afferent Investigative Site, Duncansville

24018

Afferent Investigative Site, Roanoke

27103

Afferent Investigative Site, Winston-Salem

27408

Afferent Investigative Site, Greensboro

28803

Afferent Investigative Site, Asheville

29464

Afferent Investigative Site, Mt. Pleasant

29650

Afferent Investigative Site, Greer

30329

Afferent Investigative Site, Atlanta

32806

Afferent Investigative Site, Orlando

33756

Afferent Investigative Site, Clearwater

33781

Afferent Investigative Site, Pinellas Park

38654

Afferent Investigative Site, Olive Branch

43623

Afferent Investigative Site, Toledo

45219

Afferent Investigative Site, Cincinnati

48098

Afferent Investigative Site, Troy

53142

Afferent Investigative Site, Kenosha

63042

Afferent Investigative Site, Hazelwood

63141

Afferent Investigative Site, St Louis

67203

Afferent Investigative Site, Wichita

75231

Afferent Investigative Site, Dallas

77062

Afferent Investigative Site, Houston

78209

Afferent Investigative Site, San Antonio

78229

Afferent Investigative Site, San Antonio

78705

Afferent Investigative Site, Austin

84015

Afferent Investigative Site, Clinton

85018

Afferent Investigative Site, Phoenix

85027

Afferent Investigative Site, Phoenix

87102

Afferent Investigative Site, Albuquerque

92108

Afferent Investigative Site, San Diego

97504

Afferent Investigative Site, Medford

98057

Afferent Investigative Site, Renton

02740

Afferent Investigative Site, New Bedford

02472

Afferent Investigative Site, Watertown

02886

Afferent Investigative Site, Warwick

All Listed Sponsors
lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT01554579 - A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter